Literature DB >> 12962465

Isoniazid associated, painful, bilateral gynaecomastia.

Puneet Khanna1, Chandramani Panjabi, Vikas Maurya, Ashok Shah.   

Abstract

Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy. We describe a 25-year-old, human immunodeficiency virus (HIV)--negative man, who was started on antituberculosis treatment (ATT) with isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E) in the combination RHZE for the first two months and RH there on. After four months, while receiving RH, he developed painful bilateral gynaecomastia. ATT had to be stopped because of this adverse drug reaction. Gynaecomastia, however, persisted even after three months of cessation of therapy. A year later, the patient reported complete disappearance of pain and swelling, although right breast continued to appear larger than the left.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12962465

Source DB:  PubMed          Journal:  Indian J Chest Dis Allied Sci        ISSN: 0377-9343


  5 in total

1.  Ethionamide-induced gynecomastia.

Authors:  Ramakant Dixit; Jacob George; Arun K Sharma; Naveen Chhabra; Suresh K Jangir; Vikas Mishra
Journal:  J Pharmacol Pharmacother       Date:  2012-04

2.  Isoniazid related gynecomastia: Description of a case and systematic review of literature.

Authors:  Ajmal Khan; Ritesh Agarwal
Journal:  Lung India       Date:  2012-04

Review 3.  Gynecomastia and drugs: a critical evaluation of the literature.

Authors:  Frank Q Nuttall; Rohit S Warrier; Mary C Gannon
Journal:  Eur J Clin Pharmacol       Date:  2015-04-02       Impact factor: 2.953

4.  A rare case of unilateral gynecomastia during antituberculous chemotherapy with isoniazid.

Authors:  B K Manjunatha Goud; Oinam Sarsina Devi; Bhavna Nayal; R N Devaki
Journal:  Indian J Pharmacol       Date:  2012 Jul-Aug       Impact factor: 1.200

5.  Hyperprolactinemia with Galactorrhea Due to Subclinical Hypothyroidism: A Case Report and Review of Literature.

Authors:  Kashif Aziz; Amir Shahbaz; Muhammad Umair; Mohaddeseh Sharifzadeh; Issac Sachmechi
Journal:  Cureus       Date:  2018-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.